Cargando…

Expansion of human megakaryocyte-biased hematopoietic stem cells by biomimetic Microniche

Limited numbers of available hematopoietic stem cells (HSCs) limit the widespread use of HSC-based therapies. Expansion systems for functional heterogenous HSCs remain to be optimized. Here, we present a convenient strategy for human HSC expansion based on a biomimetic Microniche. After demonstratin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yinghui, He, Mei, Zhang, Wenshan, Liu, Wei, Xu, Hui, Yang, Ming, Zhang, Hexiao, Liang, Haiwei, Li, Wenjing, Wu, Zhaozhao, Fu, Weichao, Xu, Shiqi, Liu, Xiaolei, Fan, Sibin, Zhou, Liwei, Wang, Chaoqun, Zhang, Lele, Li, Yafang, Gu, Jiali, Yin, Jingjing, Zhang, Yiran, Xia, Yonghui, Mao, Xuemei, Cheng, Tao, Shi, Jun, Du, Yanan, Gao, Yingdai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113370/
https://www.ncbi.nlm.nih.gov/pubmed/37072407
http://dx.doi.org/10.1038/s41467-023-37954-3
Descripción
Sumario:Limited numbers of available hematopoietic stem cells (HSCs) limit the widespread use of HSC-based therapies. Expansion systems for functional heterogenous HSCs remain to be optimized. Here, we present a convenient strategy for human HSC expansion based on a biomimetic Microniche. After demonstrating the expansion of HSC from different sources, we find that our Microniche-based system expands the therapeutically attractive megakaryocyte-biased HSC. We demonstrate scalable HSC expansion by applying this strategy in a stirred bioreactor. Moreover, we identify that the functional human megakaryocyte-biased HSCs are enriched in the CD34(+)CD38(-)CD45RA-CD90(+)CD49f (low)CD62L(-)CD133(+) subpopulation. Specifically, the expansion of megakaryocyte-biased HSCs is supported by a biomimetic niche-like microenvironment, which generates a suitable cytokine milieu and supplies the appropriate physical scaffolding. Thus, beyond clarifying the existence and immuno-phenotype of human megakaryocyte-biased HSC, our study demonstrates a flexible human HSC expansion strategy that could help realize the strong clinical promise of HSC-based therapies.